Annotation of rs1800497

Allele A is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to allele G.

Alleles are referred to as DRD2 A1 and A2 in the paper. It is assumed that A1 represents the A allele and A2 represents the G allele.

From Publication

Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2006. Barratt Daniel T et al.
PMID:16583408(opens in new window) DOI:10.1002/ajmg.b.30319(opens in new window)

Gene

DRD2

Variant

rs1800497

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

1449161667

Score
More info on scoring

-1.5

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    case/control, retrospective

    Study size

    166 (cases=71; controls=95)

    Association p-value

    = 1.00

    Statistical analysis

    OR: 1.05

    Confidence interval

    0.33 - 3.36

    Allele frequency

    A: case=0.19, control=0.179

    Biogeographical group
    More info on groups

    Multiple groups, Participants were of Caucasian, Indigenous Australian, Torres Strait Islander, Asian, Indian or Turkish ethnicity.

    Population description

    men; women

    Study Cohort: Case patients were opioid-dependent. 46 case patients received methadone maintenance therapy, while the remaining 25 received buprenorphine maintenance therapy. Controls were non-opioid-dependent.

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...